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105SUMMARY
Expansion of pathobionts such as adherent-invasive
Escherichia coli during inﬂammation is associated with in-
ﬂammatory bowel disease and contributes to intestinal
epithelial barrier dysfunction. This review discusses mech-
anisms by which these bacteria disrupt epithelial barrier
and tight junction function.
Pathobiont expansion, such as that of adherent-invasive
Escherichia coli (AIEC), is an emerging factor associated
with inﬂammatory bowel disease. The intestinal epithelial
barrier is the ﬁrst line of defense against these pathogens.
Inﬂammation plays a critical role in altering the epithelial
barrier and is a major factor involved in promoting the
expansion and pathogenesis of AIEC. AIEC in turn can
exacerbate intestinal epithelial barrier dysfunction by
targeting multiple elements of the barrier. One critical
element of the epithelial barrier is the tight junction.
Increasing evidence suggests that AIEC may selectively
target protein components of tight junctions, leading to
increased barrier permeability. This may represent one
mechanism by which AIEC could contribute to the devel-
opment of inﬂammatory bowel disease. This review article
discusses potential mechanisms by which AIEC can disrupt
epithelial tight junction function and intestinal barrier
function. (Cell Mol Gastroenterol Hepatol 2016;-:-–-;
http://dx.doi.org/10.1016/j.jcmgh.2016.10.004)
Keywords: Tight Junctions; Intestinal Permeability; Inﬂamma-
tory Bowel Disease.
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116Itinal microenvironment, including the intestinal
microbiome, and can result in the promotion of pathobiont
expansion.1 A clinically important example of this involves
the expansion of the adherent-invasive Escherichia coli
(AIEC) LF82, originally isolated from ileal mucosa of a
Crohn’s disease patient.2 Crohn’s disease (CD) and ulcera-
tive colitis (UC) are multifaceted conditions that collectively
are referred to as inﬂammatory bowel disease (IBD).3,4
Factors contributing to IBD onset and development
include dysregulation of gut bacteria and an increase in
intestinal epithelial barrier permeability.1 This review
article discusses the emergence of AIEC as a potential
pathogenic factor in IBD and the molecular mechanismsREV 5.4.0 DTD  JCMGH175 proof  9through which it disrupts intestinal epithelial homeostasis
and tight junction (TJ) integrity.
AIEC
Although the etiology of IBD is unknown, many in-
vestigators have probed whether a pathogenic cause can be
attributed to onset of disease, either in full or in part.5–7
Although no pathogen has been shown consistently to be
associated with IBD, a subset of CD patients do show
increased prevalence of a unique enteropathogenic strain of
the B2 phylotype E coli termed AIEC.2,8,9 Ileal biopsy spec-
imens from CD and UC patients have shown that AIEC are
associated primarily with CD; however, more recent studies
have shown an equal prevalence of AIEC strains in UC as
well as CD, suggesting that this pathobiont may have a
greater association with IBD than ﬁrst thought.10–12
Although LF82 is the most referenced AIEC, it is only one
of many AIEC strains that were found in IBD patients.2,13
It has been remarkably difﬁcult to identify a speciﬁc
genetic or molecular marker of AIEC, thus in vitro assays are
used to validate AIEC.14 However, there may be some ge-
netic signatures that differ between the B2 AIEC phylotype
compared with other AIEC phylotypes.12 One potential AIEC
candidate gene is the novel AIEC serine protease Vat-AIEC,
which promotes expansion and adherence of AIEC to
intestinal epithelial cells (IECs).15 Expression of this gene
was approximately 3-fold higher in CD-AIEC isolates
compared with non-AIEC isolates from CD patients or
healthy subjects.15 It therefore could be considered a se-
lective rather than an exclusive genetic marker for AIEC.
AIEC are distinct from other strains of E coli because
they show nonclassic virulence factors of adherence and
invasion (ie, lack of a type III secretion system).13 Notably,
AIEC pathogenesis involves survival and replication in IECsNovember 2016  4:35 pm  ce DVC
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2 Shawki and McCole Cellular and Molecular Gastroenterology and Hepatology Vol. -, No. -and macrophages in vivo and in vitro that further exacer-
bated barrier dysfunction, this topic is discussed later
(Figure 1).9,13 Martinez-Medina and Garcia-Gil16 published
an excellent comprehensive review on the deﬁnition, char-
acteristics, and molecular basis of AIEC pathogenicity.REV 5.4.0 DTD  JCMGH175 proof  9Interaction of AIEC With IECs Q
The intestine is lined by a single layer of epithelial cells
that are interconnected by transmembrane proteins to
create physical connections with one another and to form a
selectively permeable barrier.17 This leaky barrier servesFigure 1. Effect of AIEC on
major junctional proteins
and regulatory pathways in
simpliﬁed IECs. Indirect
internalization of TJ pro-
teins by a micropinocytosis
process can occur as a
result of AIEC direct or in-
direct TNF-a–dependent
activation of NF-kB, lead-
ing to increased expres-
sion of MLCK and
cytoskeletal contraction.
AIEC interaction with IECs
results in direct internali-
zation of TJ proteins and
indirectly by activation of
proinﬂammatory cytokines.
Intestinal barrier perme-
ability is compromised,
permitting the internaliza-
tion, survival, and replica-
tion of AIEC, invasion of
macrophages, and further
exacerbation of barrier
permeability. IFNG,
______________; pMLC,
phosphorylated MLC; Th,
T-helper cell. Q24
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344multiple functions that are essential for intestinal homeo-
stasis: generation of ion solute concentration gradients,
absorption of nutrients, antimicrobial peptide secretion
(reviewed by McCole and Barrett18), and protection of the
host from toxins and pathogens (reviewed by Peterson and
Artis19). Disruption of barrier function can lead to loss of
microbiome diversity and promotion of AIEC expansion and
pathogenesis.1,6
IECs express molecular sensors that sample the luminal
content for bacterial antigens, and in some cases the
bacteria itself, and translate this information to host
immune cells.19 This process prevents the host immune
system from a robust proinﬂammatory response against
commensal bacteria while maintaining the ability to protect
against pathogens. The ﬁrst identiﬁed IBD-associated gene,
cytoplasmic nucleotide-binding oligomerization domain 2
(NOD2/CARD15), a NOD-like receptor family member,
serves as a sensor to bacterial peptidoglycans (BPs)
(reviewed by Philpott et al20). Binding of BPs to NOD2 re-
sults in the activation of nuclear factor–kB (NF-kB) and
autophagolysis,21 and the appearance of NOD2 at the site of
bacterial endocytosis in epithelial cells drives autophagol-
ysis.20 Mutations in NOD2 result in an increased immune
response to bacteria and bacterial antigens22 that is
accompanied by impaired autophagolysis of AIEC and sub-
sequently survival of AIEC in immune cells.23,24 Conversely,
overexpression of NOD2 and other genes involved in auto-
phagy (eg, by activation of the EIF2AK4-EIF2A-ATF4
pathway), results in an increased autophagy response to
AIEC and a reduction in AIEC survival in macrophages.25–27
Thus, functional autophagolysis in both intestinal epithelial
cells and macrophages is required for AIEC degradation and
prevention of AIEC-induced barrier dysfunction.24
It is clear that proinﬂammatory cytokine signaling plays
a major role in altered intestinal permeability28 and this
may be associated with AIEC pathogenesis. Loss of negative
regulation of proinﬂammatory cytokines (eg, interferon-g
[IFN-g] and tumor necrosis factor-a [TNF-a]), and,
conversely, overstimulation of the proinﬂammatory
response, plays a role in altered intestinal permeability and
this may be associated with AIEC expansion and patho-
genesis.22,29–31 A key mediator of signaling by many cyto-
kines, NF-kB has been shown to regulate the development
and response of the immune system, inﬂammation, and
cancer.32 Defective NF-kB activation can result in a defective
immune cell response to BPs (driven by interleukin [IL]8)
and bacterial lipopolysaccharides, and defective
autophagy.33–35 Taken together, dysfunctional regulation of
proinﬂammatory cytokines may be associated with an
inappropriate response to AIEC and may play a role in the
promotion of AIEC expansion and pathogenesis.14
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352AIEC Adherence
With respect to the clinical intersection between altered
expression of genes in IBD and genes involved in AIEC
expansion, patients who are at risk of developing CD
also overexpress carcinoembryonic antigen–related cell-
adhesion molecule 6 (CEACAM6), placing them at a higherREV 5.4.0 DTD  JCMGH175 proof  9risk for AIEC adherence and invasion via interaction of
bacterial type 1 pili and long polar ﬁmbriae (LPF) to host
CEACAM6.36 CEACAM6, normally expressed on the apical
membrane of human epithelial cells from the large intes-
tine,37 is regulated by the proinﬂammatory cytokines IFN-g
and TNF-a.36,38 Studies using isolated human Peyer’s
patches or mouse ileal biopsy specimens containing Peyer’s
patches showed that bacterial pili speciﬁcally targeted
Peyer’s patch M-cells (discussed later) expressing CEA-
CAM6; however, LPF-independent AIEC invasion and
adherence also has been shown in other types of intestinal
epithelial cells.36,39 Nevertheless, AIEC can up-regulate
CEACAM6 indirectly via activation of proinﬂammatory
cytokines,40 thus leading to increased expression of CEA-
CAM6 and further binding and internalization of AIEC.
CEABAC10 Qtransgenic mice that overexpress human
CEACAMs show no clinical evidence of colitis; however,
these same mice infected with AIEC show a barrier defect.41
It would be expected, therefore, that patients with NOD2
mutations and/or increased expression of ileal CEACAM6
are more at risk to develop IBD. In support of this state-
ment, CEACAM6 and the pore-forming TJ protein claudin-2,
isolated from ileal biopsy specimens of CD patients, are not
only co-localized, but expression levels are both increased
compared with control subjects,41 thereby promoting a
favorable environment for AIEC adherence and invasion and
further exacerbation of barrier dysfunction, ultimately
leading to a vicious cycle of proinﬂammatory cytokine
release and increased barrier permeability. Interestingly,
although CEACAM6 is overexpressed in ileal mucosa of IBD
patients, the protein is not normally expressed in ileal
mucosa.41 The mechanism(s) regulating CEACAM6 expres-
sion in IBD currently are not known.AIEC Invasion
The mechanism of AIEC internalization involves macro-
pinocytosis and vacuolization of the bacteria into IECs and
macrophages.9,42–44 AIEC have been found in late endo-
somes of intestinal epithelial cells, as evident by co-
localization with the lysosomal marker LAMP1 Q.24,44 Simi-
larly, Mycobacterium avium subspecies paratuberculosis has
been localized in endosomes of intestinal epithelial cells.45
The process of internalization into endosomes also occurs
during reorganization of TJs and is discussed later. AIEC-
containing endosomes mature into phagolysosomes, which
then can exit IECs, as discussed later. Alternatively, AIEC
replication is permitted in autophagolysis-deﬁcient, AIEC-
containing phagosome/endosome/lysosomes, leading to
loss of organelle membrane integrity, release of the bacteria
into the cytoplasm, and basolateral exit of the bacteria from
the IEC (Figure 1).46,47 AIEC translocation through the
epithelial barrier is dependent on type 1 pili and glyco-
protein 2 binding Qof LPF to “membraneous
Q
” or “microfold”
cells (M-cells).39,43,48 M-cells are required for the develop-
ment of host immunity,49 are involved in bacterial
sampling,50–53 and can serve as an alternative gateway for
AIEC39,54 into and through the epithelium (reviewed by
Pravda55). The AIEC-containing endosome can mature into aNovember 2016  4:35 pm  ce DVC
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470phagosome and exit basolaterally from the IEC, where it can
be processed by macrophages (Figure 1).42,44
After basolateral exit from epithelial cells, AIEC exposure
to lamina propria immune cells induces a proinﬂammatory
response and a TNF-a–dependent increase in M-cell devel-
opment,56 thereby further permitting the adherence and
invasion of AIEC and exacerbation of barrier permeability.
AIEC invasion elicits a proinﬂammatory response by
triggering secretion of proinﬂammatory cytokines from
IECs, resulting in recruitment of immune cells,13,57 and,
subsequently, NF-kB signaling,13 which allows survival of
AIEC in macrophages.58 In summary, cytokines play a key
role in the pathogenesis of AIEC and AIEC-induced epithelial
barrier dysfunction.
AIEC-Dependent Disruption of the
Apical Junctional Complex
In addition to the unknown etiology of IBD, it is uncer-
tain whether inﬂammation precedes epithelial barrier
dysfunction or if barrier dysfunction results in chronic
inﬂammation such as that observed in IBD. However, some
evidence points to an underlying barrier defect that renders
individuals susceptible to disease. First-degree relatives of
CD patients show asymptomatic barrier dysfunction asso-
ciated with subclinical immune activation, indicating that a
barrier defect may precede or is at least an early event in
the disease.59,60 In addition, altered permeability across the
intestinal epithelium is a predictor of relapse in human
CD61; whereas increased permeability precedes inﬂamma-
tion in rodent models,62 canine models,63 and human dis-
ease,59,64–66 and has been shown to be the underlying
mechanism of IBD in these patients. Thus, host health is
dependent on the integrity of the epithelial barrier. Patho-
logic stimuli, such as AIEC, in part inﬂuence epithelial
barrier integrity by altering the network of proteins that
regulate barrier permeability known as the intercellular
apical junctional protein complex (AJC).67
The AJC, comprised of several different proteins with
distinct responsibilities, directs the paracellular movement
of ions and solutes and thus is responsible to maintain
appropriate epithelial barrier permeability. The structural
units of the AJC responsible for regulating barrier integrity
and permeability are adherens junctions (AJ) and apical
TJs.17 AJs and TJs are associated with scaffolding proteins
that cooperate with the cytoskeleton of the cell providing
the AJC with a dynamic means of regulation.67 Dysregulation
of TJ proteins is observed in IBD patients (Table 1).68–71
That the AJC is required for barrier integrity has led to
the hypothesis that defects in the AJC may play a role in IBD
pathogenesis. Alteration of the AJC can occur in response to
exposure to AIEC and other enteropathogenic E coli.71–74
AIEC have been shown to decrease transepithelial elec-
trical resistance of IECs owing to disruption of the AJC.47,67
The molecular interaction of AIEC with IECs induces an
inﬂammatory response leading to the overproduction of
proinﬂammatory cytokines,75 with IFN-g and TNF-a as the
major effectors, and this is a key step in the pathogenesis of
IBD. IFN-g and TNF-a both have been shown to increase gutREV 5.4.0 DTD  JCMGH175 proof  9permeability by acting on TJ proteins and TJ strand
complexity,76,77 which then further exacerbates barrier
dysfunction. AIEC-dependent, cytokine-induced alterations
in AJ and TJ proteins is discussed later.
CEACAM6
As previously discussed, an increase in expression of
both CEACAM6 and claudin-2 is associated with increased
barrier permeability. Interestingly, targeting of adherens
junction proteins, occludin, and claudin 3/4 and other tight
junction proteins by Helicobacter pylori, Vibrio cholera, and
enteropathogenic E coli, respectively, has been shown pre-
viously,85,86 Qsupporting the possibility that AIEC directly
bind to TJ proteins. It has been shown that AIEC results in
increased claudin-2 expression in mice and human beings,41
and because AIEC pathogenesis is not dependent solely on
interaction of CEACAM6 with AIEC, it is possible that
claudin-2 could serve as a gateway for AIEC entry into IECs
while co-internalization of TJ proteins and AIEC may pro-
mote AIEC invasion and increased barrier permeability.
Whether AIEC are able to bind directly to TJ proteins has yet
to be shown experimentally.
Claudin-2
Distinct from the functions of adherens junctions, TJs
serve as a paracellular gateway for passive ﬂuid movement
and solute ﬂux and limit the passive movement of proteins
and lipids, thereby generating a concentration gradient as
well as playing a role in polarization of epithelia.71 The
conglomeration of proteins that make up the TJs include the
claudin family of transmembrane proteins, junctional
adhesion molecule-A (JAM-A), occludin, and zonula occlu-
dens members 1–3 (others not included in this article are
reviewed elsewhere67) (Figure 1).
Claudin-2 is a prominent member of the claudin family
because it forms a cation-selective pore that permits para-
cellular sodium and water ﬂux.87,88 Overexpression of
claudin-2 results in an increase in epithelial barrier
permeability both in vitro and in vivo.89–92 IL13 and TNF-a
induce a barrier defect in UC by up-regulating claudin-2 to
facilitate the pore pathway, although IL6 also has been
shown to increase claudin-2 expression in intestinal
epithelial cells.93,94 That epithelial barrier leakiness is
related inversely to TJ strand complexity67 supports the
association of increased levels of claudin-2 with increased
barrier permeability in IBD.70,95 Conversely, a decrease in
claudin-2 expression results in a tighter epithelial barrier.96
E-cadherin
Adherence junctions are primarily responsible for
cell–cell recognition as well as initiating and maintaining
cell–cell contact and polarization.97 The major AJ protein is
E-cadherin, a transmembrane protein associated with the
catenin family of cytoplasmic proteins (Figure 1).97 E-cad-
herin plays a critical role in adhesion of cells and is required
for the formation of TJs.80 E-cadherin single-nucleotide
polymorphisms and dysregulation of E-cadherin are asso-
ciated with IBD (reviewed by McCole80), supporting a roleNovember 2016  4:35 pm  ce DVC
Table 1.Major AIEC-Affected Host Junctional Proteins and Mutations Associated With IBD
Protein Gene Function Impact of AIEC Mechanisms
IBD
References
CEACAM6 CEACAM6/
CD66c/
CEAL/NCA
Bacterial pili receptor
recognizing AIEC
Increase in
expression
IFN-g and TNF-a
indirect induction
36,40
Claudin-2 CLDN2 Paracellular transport of Naþ
and H2O; regulates leak
pathway; major integral
protein of TJs
Increase in
expression
IFN-g, TNF-a, and
MLCK-dependent
internalization
78
E-cadherin CDH1 Major adherens junction
protein; cell–cell
adhesion and
communication
Displace E-cadherin
in vitro
Presumed TNF-a, IFN-g,
and MLCK-induced
internalization; cleavage?
47,79,80
JAM-A F11R Regulator of TJ assembly;
leukocyte transmigration
Decrease in
expression
Presumably macrophage
release of
proinﬂammatory cytokines
69,81
MLCK MYLK Phosphorylates myosin
regulatory light chains
to facilitate myosin
interaction with actin
ﬁlaments to produce
contractile activity;
membrane distribution
(and redistribution) of
TJ proteins
Down-regulation
of ZO-1,
redistribution
of TJ proteins
TNF-a–dependent activation
of NF-kB and activation
of MLCK
67,82
NOD2 CARD15 Recognition of pathogen-
associated molecular
patterns; bacterial
sensing; drive
autophagolysis of bacteria
containing phagosomes
Decrease in expression;
indirect: LPS binding
with NOD2 results
in autophagolysis
of AIEC
Endocytosis
Activation of NF-kB leading
to dysregulated
proinﬂammatory response
and promotes invasion
of AIEC
20,21,35
Occludin OCLN Integral TJ protein involved
in stability and cytokine-
induced regulation of TJs
Redistribution/down-
regulation of
occludin
Induction of TNF-a,
activation of MLCK
69,83
Partitioning
defective
protein-3
(PAR-3)
PARD3 Asymmetric cell growth;
cell polarization;
targeting of TJ proteins
to membrane
Unknown Presumably disruption of
adherens junctions resulting
in increased Cldn-2 and
decreased membrane
localization of ZO-1
80,84
Zonula
occludens-1
TJP1 Plaque protein; scaffolding
of TJ proteins to the
cytoskeleton
Disruption of
ZO-1 resulting
in increased
appearance of gaps
between cells
Presumably TNF-a, IFN-g,
and MLCK- induced
internalization
47,78,79
- 2016 AIEC Disruption 5
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588for AJ defects in IBD-associated barrier dysfunction.67
Furthermore, AIEC, in addition to other intestinal patho-
gens,80 are able to displace E-cadherin in vitro,47,79 poten-
tially providing another mechanism of invasion and barrier
disruption.
Junctional Adhesion Molecule
JAM-A is another PSD95-DlgA-zonula occludens-1 ho-
mology domain (PDZ)-domain–containing integral protein
localized to TJs.98 JAM-A shows PDZ-domain–dependent
interactions with the scaffolding protein zonula occludens 1
(ZO-1) and cell polarity partitioning defective protein-3.99
Expression of JAM-A was shown to be decreased69
together with ZO-1100 in IBD, and loss of JAM-A results inREV 5.4.0 DTD  JCMGH175 proof  9increased epithelial barrier permeability.101,102 It is un-
known whether AIEC directly results in the down-regulation
of JAM-A or if it is a consequence of down-regulation of
ZO-1; however, AIEC may regulate JAM-A indirectly via the
release of inﬂammatory cytokines from infected macro-
phages.81 Nevertheless, it is possible that AIEC, in addition
to altering ZO-1, may alter JAM-A and partitioning defective
protein-3–dependent targeting of TJ proteins to the mem-
brane,84 resulting in disrupted TJ complex integrity and
altered cell polarity, further promoting IBD pathogenesis.
Occludin
Occludin, a 65-kilodalton integral transmembrane pro-
tein, is involved in the stability and regulation of TJs.103November 2016  4:35 pm  ce DVC
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706Although down-regulation of occludin is observed in CD and
UC patients,69 the UC-associated proinﬂammatory cytokine
IL13 alone was not able to abolish occludin protein levels in
a colorectal cancer cell line (HT-29).93 This discrepancy was
attributed to a dilution of the number of cells isolated from
the inﬂamed tissue of UC patients. Nevertheless, it has been
shown from in vitro work that occludin plays a key role in
promoting barrier function and is redistributed away from
tight junctions after EHEC infection of human colonoid
monolayers.17,74 Further work to elucidate the in vivo role
of occludin is needed because mice lacking occludin do not
show defects in TJ morphology despite histologic abnor-
malities in some tissues.104 Proinﬂammatory cytokine-
dependent phosphorylation of myosin light chain (MLC)
by myosin light chain kinase (MLCK) or Rho-associated
kinase results in rapid reorganization of the AJC.67,83,105
Although it remains to be conﬁrmed, AIEC could affect
occludin distribution indirectly through bacteria-dependent
induction of proinﬂammatory cytokines from immune cells,
activation of MLCK or Rho-associated kinase, and subse-
quent redistribution of occludin.
Zonula Occludens
ZO is a PDZ homology domain containing plaque protein
involved in scaffolding of TJ proteins to the cytoskeleton.106
ZO-1, -2, and -3 contain PDZ domains that facilitate
anchorage of TJ proteins such as claudins,107 occludin,108
and JAM-A100 to the cytoplasm and thereby play a key
role in TJ formation and regulation. TNF-a induces an
increase in TJ permeability via NF-kB–dependent down-
regulation of ZO-1 protein and MLCK-depend-
ent82,83,109–111 redistribution of TJ proteins76 in an
apoptosis-independent manner (reviewed by Bruewer
et al67). Similarly, AIEC disrupt TJ composition by altering
ZO-1, resulting in increased appearance of gaps between
cells.47,79 Conversely, probiotic and commensal bacteria
promote up-regulation of ZO proteins and strengthening of
the epithelial barrier (reviewed by Ulluwishewa et al112),
potentially supporting the notion that when probiotic bac-
teria outcompete pathogens, this not only will return the
balance of the microbiota, but also enable restitution of the
TJ complex.
In the absence of bacteria, regulation of the AJC is
mediated by the interaction of the cytoskeleton with the
proteins of the AJC or by cytokines. IFN-g induces macro-
pinocytosis78 of occludin, JAM-A, and claudin-1 via myosin
2–dependent vacuolarization of the apical membrane105
into early endosomes, resulting in an increase in barrier
permeability.113 That AIEC also are internalized by macro-
pinocytosis illustrates a direct disruption of the AJC by the
bacteria and establishes an additional virulence factor for
the invasion of AIEC.
Conclusions
Data to date clearly support the notion that IBD patho-
genesis is dependent on dysregulation of multiple factors
including disruption of the intestinal barrier and immune
dysregulation, and is associated with profound alterations inREV 5.4.0 DTD  JCMGH175 proof  9gut microbial communities. Altered intestinal homeostasis
drives expansion of AIEC and results in compromised bar-
rier function. AIEC are able to invade, survive, and replicate
within host cells, leading to exacerbation of barrier
dysfunction by disruption of TJ proteins, and ultimately
attributing Qto IBD pathogenesis. Recent clinical ﬁndings
have indicated that AIEC is not associated exclusively with
ileal CD. If AIEC does indeed play an important role in IBD
pathogenesis it will be vital to better understand unresolved
questions regarding its appearance in disease. Speciﬁcally:
(1) what are the host genetic and environmental factors that
promote AIEC expansion in some patients but not all; (2)
how is regional variation in AIEC expansion determined;
and (3) can therapeutic interventions (probiotics, prebiotics,
small molecules) speciﬁcally neutralize or modify AIEC
pathogenic behavior? AIEC are capable of compromising
intestinal epithelial barrier properties both directly and
indirectly to enhance their pathogenic impact. Therefore, in
addition to the earlier-described approaches, it will be of
key interest to determine if strategies designed to enhance
the epithelial barrier can minimize the pathogenic impact of
AIEC and its putative contribution to IBD.References
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